Milrinone
Primacor · Milirinone · Milrinone USP · YM-018 · Minong · Milrila · Corotrop · win47203
식별자 및 물리적 특성
| CAS No. | 78415-72-2 |
|---|---|
| 분자식 | C12H9N3O |
| 평균 분자량 | 211.22 g/mol |
| 단동위원소 질량 | 211.07456191 g/mol |
| SMILES | Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1 |
| InChIKey | PZRHRDRVRGEVNW-UHFFFAOYSA-N |
| PubChem CID | 4197 |
| ChEMBL | CHEMBL189 |
| ChEBI | CHEBI:50693 |
| EC No. | 278-903-6 |
| DTXSID | DTXSID5023324 |
화학 및 물리적 성질
| XLogP | 0 |
|---|---|
| 극성 표면적 | 65.8 |
| 수소 결합 공여자 수 | 1 |
| 수소 결합 수용자 수 | 3 |
| 회전 가능 결합 수 | 1 |
| 무거운 원자 수 | 16 |
| 형식 전하 | 0 |
| 복잡도 | 419 |
| 의약품 | PharmaceuticalsPharmaceuticals -> Listed in ZINC15 |
| LogP(분배 계수) | 0.40.42 |
| 용해도 | <1 mg/mL2.09e-01 g/LDMSO: >10mg/mL |
| Human Drugs | Pharmaceuticals |
| 녹는점 | >300 °C> 300 °C>3000C |
| Physical Description | Solid |
| Collision Cross Section | 157.1 Ų [M+H]+ [CCS Type: DTBuffer gas: N2Ionization: APCI+Dataset: TOXCASTSource Identifier: DTXSID5023324]150.4 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)] |
| 끓는 점 | 350.9°C (rough estimate) |
| 밀도 | 1.1922 (rough estimate) |
| 굴절률 | 1.5700 (estimate) |
| 저장 조건 | 2-8°C |
| 물리적 상태 | 가루 |
| pKa(산도 계수) | 7.21±0.10(Predicted) |
| 색상 | 회백색 |
| 용해도 | DMSO에 용해됩니다. 물에 불용성. |
| Merck | 14,6197 |
| 안정성 | 안정적인. 강한 산화제와 호환되지 않습니다. |
| InChI | InChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16) |
| InChIKey | FYEJSUDMDUIMKJ-UHFFFAOYSA-N |
| SMILES | C1(C)NC(=O)C(C#N)=CC=1C1C=CN=CC=1 |
화학적 성질
Crystalline Solid
안전 및 규제
| GHS 분류 | DangerH301+H311+H331 (38.4%): Toxic if swallowed, in contact with skin or if inhaled [Danger Acute toxicity, oralacute toxicity, dermalacute toxicity, inhalation]P261, P262, P264, P270, P271, P280, P301+P316, P302+P352, P304+P340, P316, P321, P330, P361+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 73 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 3 (100%) |
| 유해 작용 | The most feared adverse effect of milrinone is its potential to induce hemodynamic changes and arrhythmias. Milrinone may cause ventricular tachyarrhythmia, leading to cardiac ischemia or sudden cardiac death. These changes are not shown to follow a dose-dependent relationship. Milrinone can cause an increase in venous vessel capacitance, leading to decreased preload and manifesting as headaches, syncope, and severe hypotension. Unlike tachyarrhythmias, hypotension occurs in a dose-dependent relationship. |
| 독성 요약 | Cardiovascular toxicity is primarily seen in chronically milrinone patients and manifests as tachyarrhythmias and sudden cardiac death. At high dosing, patients may also experience hypotension and syncope. Milrinone had a previous use as an oral formulation for outpatient use in patients with NYHA class III and IV chronic heart failure (CHF) to improve symptoms and decrease the frequency of hospital admissions. However, this practice was discontinued following the PROMISE trial in 1991 due to safety concerns. This double-blinded clinical trial assessed patients with CHF class III/IV placed on milrinone or placebo and ended early due to increased mortality in the milrinone group secondary to ventricular tachyarrhythmias and sudden cardiac death. |
| 수질 위해 등급(WGK) | 3 |
| RTECS 번호 | DW1762000 |
| 운송 번호(UN) | UN 2811 6.1/PG 3 |
| 관세 코드 | 29337900 |
| 위험 문구(R) | 23/24/25-26/27/28 |
| 위험 표시 | T,T+ |
| 안전 문구(S) |
용도
개요
Milrinone, an inhibitor of phosphodiesterase selective for fraction III PDE, exerts a positive inotropic effect on the heart as well as a peripheral vasodilatory effect. Milrinone given intravenously produces significant improvements on cardiac output, pulmonary capillary wedge pressure and vascular resistance without significant effects on the heart rate.
용도
It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. Milrinone inhibits the action of phosphodiesterase-3 preventing degradation of cAMP. The corresponding increase in cAMP levels leads to increased activation of protein kinase A. It is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity.
일반 설명
Milrinone, 1,6-dihydro-2-methyl-6-oxo-3,4＇-bipyridine-5-carbonitrile (Primacor), is another dipyridinephosphodiesterase F-III inhibitor that possesses pharmacologicalproperties similar to those of amrinone. The inhibitionof the degradation of cAMP results in an increase in the cardiacmuscle’s force of contraction.